Genetic basis of HIV-1 resistance and susceptibility: An approach to understand correlation between human genes and HIV-1 infection

Indian Journal of Experimental Biology

Volumn 44, Issue 9, 2006, Pages 683-692

  Kumar, Vijay ^a   Prakash, O ^b   Manpreet, S ^b   Sumedh, G ^b   Medhi, B ^b  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

AIDS; HIV 1; HLA; MHC

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR;

ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INNATE IMMUNITY; ISOLATION AND PURIFICATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MUTATION; PHYSIOLOGY; REVIEW;

CHEMOKINES; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MUTATION; RECEPTORS, CHEMOKINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748606354     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Fauci A S. The AIDS epidemic - considerations for the 21st centuary, N Engl J Med, 341 (1999) 1046.
2. Kaposi sarcoma and pneumocystis pneumonia among homosexual men - Newyork City and California, Morb Mortal Wkly Rep, 30 (1981) 305.
3. Pneumocystis pneumonia - Los Angeles, Morb Mortal Wkly Rep, 30 (1981) 250.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS), AIDS epidemic updatehttp://www.unaids.org/worldaidsday/2002/press/Equipdate.html(UNAIDS, Geneva) 2005.
5. Joint United Nations Programme on HIV/AIDS (UNAIDS), Report on global HIV/AIDS epidemic (UNAIDS, Geneva) 2005.
6. Annan K A, In Africa, AIDS has a woman's face, Newyork Times 29 December (2002) 9.
7. Robbin A Weiss, HIV and AIDS: Looking ahead, Nat Med, 9 (2003) 887.
8. E A Berger, Murphy P M, & J M Farber, Chemokine receptors as HIV-1 coreceptors: in viral entry, tropism and disease, Ann Rev Immunol, 17 (1999) 657.
9. O Brien S J, Nelson G W, Winkler CA & Smith MW, Polygenic and multifactorial disease genes association in man lesson from AIDS, Ann Rev Genet, 34 (2000) 563.
10. O' Brien S J & Dean M, In search of AIDS resistance genes, Sci Am, 277 (1997) 44.
11. O'Brien S J, AIDS: A role for host genes, Hosp Pract, 33 (1998) 53.
12. Phair J, Jacobson L, Detels R, Rinaldo C, Saah A, Schrager L, et al, AIDS occurring within 5 years of infection with HIV-I, The multicentre AIDS cohort study, J Acqouir Immune Def Syndr, 5 (1992) 490.
13. Kaslow R A, Ostrow DG, Detels R, Phair J, Polk BF & Rinaldo CR jr, The multicentre AIDS cohort study - Rationale, organization, and selected characteristics of the participant, Am J Epidemiol, 26 (1987) 310.
14. Detels R, Liu Z, Hennessey K, Kan J, Visscher BR, Taylor JM, et al, For the multicentre AIDS cohort study: Resistance to HIV infection, J Acqouir Immune Def Syndr, 7 (1994) 1263.
15. Gullick R M, New antiretroviral drugs, Clin Microbiol Infect, 9 (2003) 186.
16. O' Brien S J & Nelson G W Human genes that limit AIDS, Nat Genet, 36 (2004) 565.
17. Carrington M, Nelson G & O' Brien S J, Considering genetic profile in functional studies of immune responsiveness to HIV-I, Immunol Lett, 79 (2001) 131.
18. O' Brian S J & Moore J, The effect of genetic variation in chemokines and their receptors on HIV-1 transmission and progression to AIDS, Immunol Rev, 177 (2000) 99.
19. Michael Dean, Mary Carrington, Cheryl Winkler, Gavin A. Huttley, Michael W Smith, Rando Allikmets et al, Genetic restriction HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene, Science, 273 (1996) 1856.
20. Wu L, W A Paxton, N Kassam, N Ruffing, J B Rottman, N Sullivan et al., CCR5 levels and expression, pattern correlate with infectibility by macrophage-tropic HIV-1 in vitro, J Exp Med, 185 (1997) 1681.
21. Benkirane M, Jin D Y, Chun R F, Koup R A & Jeang K T et al., Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection CCR5 Delta 32, J Biol Chem, 272 (1997) 30603.
22. Stephens J C, Reich DE, Goldstein, D B, Shin H D, Smith M W, Carrington M et al, Dating the origin of the CCR5 Delta 32 AIDS resistance allele by the coalescence of haplotypes, Am J Hum Genet, 62 (1998) 1507.
23. Galvani A P & Slatkin M, Evaluating plague and smallpox as historical selective pressure for the CCR5 Delta 32 HIV resistance allele, Proc Natl Acad Sci USA, 100 (2003) 15276.
24. Maureen P Martin, Michael Dean, Michael W Smith, Cheryl Winkler Bernard Gerrard, Nelson L Michael et al, Genetic acceleration of AIDS progression by promoter variant of CCR5, Science, 282 (1998) 1907.
25. Carrington M, Dean M, Martin M P & O Brien S J, Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences, Hum Mol Genet, 8 (1999) 1939.
26. Salkowitz JR, Bruse SE, Meyerson H, Valdez H, Mosier DE, Harding CV, Zimmerman PA, Lederman MM et al, CCR5 Promoter polymorphism determines macrophages CCR5 density and magnitude of HIV-1 propagation in vitro, Clin Immunol, 108 (2003) 234.
27. Bream J H & Young H A, CCR5 promoter alleles distinguished by specific DNA binding factor, Science, 284 (1999) 223a.
28. Benhur Lee, Benjamin J, Doranz, Shalini Rana, Yanji Yi, Mario Mellado & Jose M R Frade et al, Influence of the CCR2-V641 polymorphism on HIV type 1 coreceptor activity and on chemokine receptor function of CCR2b, CR3,CCR5 and CXCR4, J Virol, 72 (1998) 7450.
29. Mariani R, Wong S, Mulder LC, Wilkinson DA, Reinhart AL, La Rosa G et al, CCR2-V641 polymorphism is not associated with altered CCR5 expression or coreceptor function, J Virol, 73 (1999) 2450.
30. Mellado M, Rodriguez-Frade, J M, Vila-Coro A J de Ana A M & Martinez-A C, Chemokine control of HIV-1 infection, Nature, 400 (1999) 723.
31. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF et al, C-C chemokines, pivotal in protection against HIV type 1 infection, Proc Natl Acad Sci USA, 95 (1998) 3857.
32. Gallo R C, Garinzo-Demo A & DeVico A L, HIV-infection and pathogenesis: What about chemokines? J Clin Immunol, 19 (1999) 293.
33. An P, Nelson GW, Wang L, Donfield S, Goedert J J, Phair J et al, Modulation of HIV infection and disease progression by interacting RANTES variants, Proc Natl Acad Sci USA, 99 (2002) 10002.
34. Cheryl Winkler, William Modi, Michael W. Smith, George W. Nelson, Xueyun Wu, Mary Carrington et al, Genetic restriction AIDS pathogenesis by SDF-1 chemokine gene variant, Science, 279 (1998) 389.
35. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA et al, The lymphocyte chemo attractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry, Nature, 382 (1996) 829.
36. Duggal P, An P, Beaty TH, Strathdee SA, Farzadegan H, Markham RB et al, Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African-Americans, Genes Immun, 4 (2003) 245.
37. Modi WS, Goedert JJ, Strathdee S, Buchbinder S, Detels R, Donfield S et al, Directional selection in the MCP-1, MCP-3 Eotaxin gene cluster influences HIV-1 transmission, AIDS, 17 (2003) 2357.
38. Enrique Gonzalez, Hemant Kulkarni, Hector Bolivar, Andrea Mangano, Racquel Sanchez, Gabriel Catano et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility, Science, 307 (2005) 1434.
39. Menten P, Wuyts A & Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev, 13 (2002) 455.
40. Townson JR, Barcellos LF & Nibbs R J, Gene copy number regulates the production of the human chemokine CCL3-L1, Eur J Immunol, 32 (2002) 3016.
41. Bugenja Matthew J A, Booth David R A, Bennetts Bruce H B, Guerin Jan C, Kaldor John M C, Stewart Graeme J A et al, Analysis of the CCL3-L1 gene for association with HIV-1 susceptibility and disease progression, AIDS, 18 (2004) 1069.
42. Charles R Mackay, CCL3L1 dose and HIV- susceptibility, TRENDS Immunol, 26 (2005) 1.
43. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert J J et al, Genetic restriction of HIV-1 infection and AIDS progression by promoter alleles of IL-10, Proc Natl Acad Sci USA, 97 (2000) 14467.
44. Bream J H, An P Zhang X, Winkler C A, & Young H A et al, A single nucleotide polymorphism in the proximal IFN-γ promoter alters control of gene transcription, Genes Immun, 3 (2002) 165.
45. An P, Vlahov D, Margolick JB, Phair J, O'Brien TR, Laute N Berger J A et al, TNF-inducible promoter variant of interferon gamma accelerates CD4 T-cell depletion HIV-1 infected individuals, J Infect Dis, 188 (2003) 228.
46. Henry AF Stephens, HIV-1 diversity versus HLA class 1 polymorphism, TRENDS Immunol, 26 (2005) 41.
47. Marsh S G E, Parham P & Barber L D, The HLA Facts Book. Academic Press, 2000.
48. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D et al, The selective down regulation of class1 major histocompatibility complex proteins by HIV-1 protects HIV infected cells from NK cells, Immunity, 10 (1999) 661.
49. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ et al, HLA and HIV-1: heterozygote advantage and β35-Cw*04 disadvantages, Science, 283 (1999)1748.
50. Ronald E Bontrop & David I Watkins, MHC polymorphism: AIDS susceptibility in non human primates, TRENDS Immunol, 26 (2005) 227.
51. Aguado B, Bahram B, Beck S, Campbell R D, Forbes S A & Geraghty D et al., Complete sequence and gene map of Human MHC, Nature, 401 (1999) 921.
52. Sette A & Sidney J, Nine major HLA class1 supertypes account for the vast preponderance of HLA-A and HLA-B polymorphism, Immunogenetics, 50 (1999) 201.
53. Parham P, Immunogenetics of killer-cell immunoglobulin-like receptors, Tissue Antigens, 62 (2003) 194.
54. Gao X ,Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert J J, Buchbinder S, Hoots K, Vlahov D, O'Brien SJ, Carrington M et al, Effects of single aminoacid change in MHC class1 molecules on the rate of progression to AIDS, N Engl J Med, 344 (2001) 1668.
55. Martin M P, Lee Gao X, Nelson J H, Detels G W, Goedert R, Buchbinder J J, et al., Epistatic interaction between KIR3SD1and HLA-B delays the progression of AIDS, Nature Genet, 31 (2002) 429.
56. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, Ball TB et al., Influence of HLA supertypes on susceptibility and resistance to HIV type 1 infection, J Infect Dis, 181 (2000) 1581.
57. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ et al., Influence of combination of human major histcompatibility complex genes on the course of HIV-1 infection, Nat Med, 2 (1996) 405.
58. Lardy NM, vander Horst AR, van de Weerd MJ, de Waal LP, Bontrop RE et al., HLA-DRB4 gene encoded HLA-DR53 specificity segregating with the HLA-DR7-DQ8 haplotype: unusual association, Hum Immunol, 59 (1998) 115.
59. Sette A & Sidney J, Nine major HLA class1 supertypes account for the vast preponderance of HLA-A and HLA-B polymorphism, Immunogenetics, 50 (1999) 201.
60. Marcus Altfeld, Marylyn M Addo, Eric S Rosenberg, Frederick M Hecht, Paul K Lee, Martin Vogel et al, Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection, AIDS, 17 (2003) 2581.
61. Mathias Lichterfeld, Xu G Yu, Sylvie Le Gall & Marcus Altfeld, Immunodominace of HIV-specific CD8+ T-cell responses in acute HIV-1 infection, TRENDS Immunol, 26 (2005) 165.
62. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M et al, HIV evolution: CTL escape mutation and reversion after transmission, Nat Med, 10 (2004) 282.
63. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al, Association between the presence of HLA-B*5701, HLA-DR7, and HLADQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir, Lancet, 359 (2002) 727.
64. Dorak MT, Tang J, Tang S, Penman-Aguilar A, Coutinho RA, Goedert JJ, et al. Influence of HLA-B 22 alleles on he course of HIV type I infection in cohort of white men, J Infec Dis, 188 (2003) 856.
65. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, et al, New Class I & II HLA alleles strongly associated with opposite pattern of progress to AIDS, J Immunol, 162 (1999) 6942.
66. Kollnberger S, Bird LA, Roddis M, Hacquard-Bouder C, Kubagawa H, Bodmer HC,et al, Fully functional HLA -B 27 restricted CD4(+) as well as CD8(+) T cell response in TCR transgenic mice, J Immunol, 172 (2004) 155.
67. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM et al, Evolution and transmission of CTL escape mutations in HIV infection, Nature, 412 (2001) 334.
68. Tang J, Tang S, Lobashevsky E, Myracle AD, Fideli U, Aldrovandi G et al, Favorable and unfavorable HLA class 1 allele sand haplotypes in Zambians predominantly infected with clade C HIV-type1, J. Virol, 76 (2002) 8276.
69. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Flores-Villanueva PO & Yunis EJ, Control of HIV-1 viraemia and protection from AIDS are associated with HLA-Bw4 homozygosity, Proc Natl Acad Sci USA, 98 (2001) 5140.
70. Stephen J O Brien, Xiaojiang Gao & Mary Carrington, HLA and AIDS: a cautionary tale, TRENDS Mol Med, 7 (2001) 379.
71. Collins K L, Chen B K, Kalams S A, Walker, B D & Baltimore D, HIV-1 nef protein protect infected primary cell against killing by CTLs, Nature, 391 (1998) 397.
72. Mangasarian A, Piguet V, Wang JK, Chen YL, Trono D, Nef induce CD4 and MHC-1 downregulation are governed by distinct determinants: N-terminal α helix and proline repeat of new Nef selectively regulate MHC-1 trafficking, J Virol, 73 (1999)1964.
73. Yamada T, Kaji N, Odawara T, Chiba J, Iwamoto A, Kitamura Y, Proline 78 is crucial for HIV-1 Nef to down regulate class I leukocyte antigen, J Virol, 77 (2003)1589.
74. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA et al, HIV-1 specific cytotoxic T lymphocytes, HLA-A11 and chemokine related factors may act synergistically to determine HIV resistance in CCR5- Delta 32 negative female sex workers in Ching Rai, northern Thailand, AIDS Res Hum Retroviruses, 17 (2001) 719.
75. Li L & Bouvier M, Structure of HLA-A1101 complexed with immunodominant nonamer and decamer HIV-1 epitope clearly reveal the presence of a middle, secondary anchor residue, J Immunol, 172 (2004) 6175.
76. Frahm N, Korber B T, Adams C M, Szinger J J, Draenert R, Addo M M & Feeney M E, Consistent cytotoxic-T-lymphocytes targeting of immunodominant regions in HIV across multiple ethnicities, J Virol, 78 (2004) 2187.
77. Yu XG, Addo MM, Perkins BA, Wej F, Rathod A, Geer SC et al, Differences in the expressed HLA class 1 alleles effect the different clustering of HIV type 1-specific T cell responses in infected chinese and caucasoids, AIDS Res Hum Retroviruses, 20 (2004) 557.
78. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, & Rowland-Jones S, Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide specific, Eur J Immunol, 34 (2004) 1673.
79. Marsh SGE, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D et al, Killer cell immunoglobulin-like receptor (KIR) nomenclature report, Tissue Antigens, 62 (2003) 79.
80. de Souza MS, Karnasuta C, Brown AE, Markowitz LE, Nitayaphan S, Garner RP et al, Comparative study of the impact of HIV infection on natural killer cell number and function in Thais and North Americans, AIDS Res Hum Retroviruses, 16 (2000) 1061.
81. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV et al, Increased NK cell activity in HIV-1 expose but uninfected Vietnamese intravascular drug users, J Immnol, 171 (2003) 5663.
82. Arthur LO, Bess JW Jr, Sowder RC, Benveniste RE, Mann DL, Chermann JC & Henderson LE, Cellular protein bound to immunodeficiency viruses: implication for pathogenesis and vaccine, Science, 258 (1992) 1935.
83. Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T et al, Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection, Lancet, 363 (2004) 518.
84. MacDonald KS, Embree J, Njenga S, Nagelkerke NJ, Ngatia I, Mohammed Z et al, Mother-child class 1 HLA concordance increases perinatal HIV-1 transmission, J Infect Dis, 177 (1998) 551.
85. Corey B Moore, Mina John, Ian R James, Frank T Christiansen, Campbell S Witt, Simon A Mallal, Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level, Science,296 (2002) 1439.
86. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E et al, Advantage of a rare HLA super type in HIV disease progression, Nat Med, 9 (2003) 928.